A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Principal Investigator

Brian O'Sullivan

Study Number

F18074

Summary

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.

Phase

N/A

Contact

Barbara Rodgers

Available at the following location(s)

• Manchester

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms